Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravidasvir + Danoprevir/r + Ribavirin in Treatment-naive, Non-cirrhotic HCV Genotype 1
NCT03362814Phase 3Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jul 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ravidasvir in hepatitis C (HCV) (2 arms), sponsored by Ascletis Pharma Inc. Primary endpoints: Sustained Virologic Response 12 weeks after EOT and Adverse events leading to permanent discontinuation of study drug. Started Jul 2017; status: completed.
02
Drugs
ravidasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03362814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03362814.